Tilmacoxib

Drug Profile

Tilmacoxib

Alternative Names: JTE 522

Latest Information Update: 23 Sep 2003

Price : $50

At a glance

  • Originator Japan Tobacco
  • Developer Fujisawa; Japan Tobacco
  • Class Antineoplastics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Apoptosis stimulants; Cyclo-oxygenase 2 inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Familial adenomatous polyposis; Osteoarthritis; Postoperative pain; Rheumatoid arthritis

Most Recent Events

  • 23 Sep 2003 Discontinued - Phase-II for Familial adenomatous polyposis in Japan (unspecified route)
  • 23 Sep 2003 Discontinued - Preclinical for Postoperative pain in Japan (unspecified route)
  • 23 Sep 2003 Discontinued - Phase-II for Rheumatoid arthritis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top